Atherosclerosis
Volume 205, Issue 1 , Pages 290-295 , July 2009

Synergistic role of inflammation and insulin resistance as coronary artery disease risk factors in African Americans and Caucasians

  • Erdembileg Anuurad

      Affiliations

    • Department of Medicine, University of California, Davis, CA, United States
    • ,
  • Russell P. Tracy

      Affiliations

    • Department of Pathology, University of Vermont, United States
    • ,
  • Thomas A. Pearson

      Affiliations

    • Department of Family and Community Medicine, University of Rochester, Rochester, NY, United States
    • ,
  • Kyoungmi Kim

      Affiliations

    • Department of Public Health Sciences, University of California, Davis, CA, United States
    • ,
  • Lars Berglund

      Affiliations

    • Department of Medicine, University of California, Davis, CA, United States
    • The VA Northern California Health Care System, United States
    • Corresponding Author InformationCorresponding author at: Department of Medicine, University of California, Davis, UCD Medical Center, CTSC, 2921 Stockton Blvd, Suite 1400, Sacramento, CA 95817, United States. Tel.: +1 916 703 9120; fax: +1 916 703 9124.

Received 3 September 2008 ,Revised 31 October 2008 ,Accepted 23 November 2008.

References 

  1. Martin BC, Warram JH, Krolewski AS, et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet. 1992;340:925–929
  2. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106:453–458
  3. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med. 1989;320:702–706
  4. Hak AE, Pols HA, Stehouwer CD, et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J Clin Endocrinol Metab. 2001;86:4398–4405
  5. Carantoni M, Abbasi F, Warmerdam F, et al. Relationship between insulin resistance and partially oxidized LDL particles in healthy, nondiabetic volunteers. Arterioscler Thromb Vasc Biol. 1998;18:762–767
  6. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–1935
  7. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  8. Nakanishi N, Shiraishi T, Wada M. Association between C-reactive protein and insulin resistance in a Japanese population: the Minoh Study. Intern Med. 2005;44:542–547
  9. Lee IT, Lee WJ, Huang CN, Sheu H-H. The association of low-grade inflammation, urinary albumin, and insulin resistance with metabolic syndrome in nondiabetic Taiwanese. Metabolism. 2007;56:1708–1713
  10. Festa A, Hanley AJ, Tracy RP, D’Agostino R, Haffner SM. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation. 2003;108:1822–1830
  11. Chen J, Wildman RP, Hamm LL, et al. Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004;27:2960–2965
  12. Paultre F, Pearson TA, Weil HF, et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol. 2000;20:2619–2624
  13. Anuurad E, Rubin J, Lu G, et al. Protective effect of apolipoprotein E2 on coronary artery disease in African Americans is mediated through lipoprotein cholesterol. J Lipid Res. 2006;47:2475–2481
  14. Philbin EF, Weil HF, Francis CA, et al. Race-related differences among patients with left ventricular dysfunction: observations from a biracial angiographic cohort. Harlem-Bassett LP(A) Investigators. J Card Fail. 2000;6:187–193
  15. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997;43:52–58
  16. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  17. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol. 1957;17:237–246
  18. Adler AI, Levy JC, Matthews DR, et al. Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67). Diabet Med. 2005;22:306–311
  19. Miller M, Mead LA, Kwiterovich PO, Pearson TA. Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease. Am J Cardiol. 1990;65:1–5
  20. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–369
  21. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477–1482
  22. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  23. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002;25:1135–1141
  24. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–1397
  25. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843
  26. Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA. 1987;258:1183–1186
  27. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004;53:693–700
  28. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation. 2003;107:391–397
  29. Festa A, D’Agostino R, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42–47
  30. Meng YX, Ford ES, Li C, et al. Association of C-reactive protein with surrogate measures of insulin resistance among nondiabetic US from National Health and Nutrition Examination Survey 1999–2002. Clin Chem. 2007;53:2152–2159
  31. Freeman DJ, Norrie J, Caslake MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51:1596–1600
  32. Mennen LI, Balkau B, Charles MA, D’Hour A, le Mauff JM. Gender differences in the relation between fibrinogen, tissue-type plasminogen activator antigen and markers of insulin resistance: effects of smoking. D.E.S.I.R. Study Group. Data from an Epidemiological Study on Insulin Resistance Syndrome. Thromb Haemost. 1999;82:1106–1111
  33. Schenk S, Saberi M, Olefsky J. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest. 2008;118:2992–3002
  34. Anuurad E, Tracy RP, Pearson TA, Beckett L, Berglund L. Comparison of C-reactive protein and metabolic syndrome as cardiovascular risk factors in African-Americans and European-Americans. Am J Cardiol (2009), doi:10.1016/j.amjcard.2008.10.016.

PII: S0021-9150(08)00838-1

doi: 10.1016/j.atherosclerosis.2008.11.028

Atherosclerosis
Volume 205, Issue 1 , Pages 290-295 , July 2009

Article Tools

* Image Usage & Resolution